Global Alzheimer’s Disease Clinical Trials Review, H2, 2018 Featuring Pfizer, J&J, Eisai Co, F. Hoffmann-La Roche, Eli Lilly and Co, Novartis, AstraZeneca, Allergan, GlaxoSmithKline & AbbVie - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 25, 2019--The “Alzheimer’s Disease Global Clinical Trials Review, H2, 2018” clinical trials has been added to ResearchAndMarkets.com’s offering.
“Alzheimer’s Disease Global Clinical Trials Review, H2, 2018” provides an overview of Alzheimer’s Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer’s Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). These reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
Key Topics Covered:
For more information about this clinical trials report visit https://www.researchandmarkets.com/research/m8h8v6/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190225005516/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Clinical Trials,Alzheimer’s Disease Drugs
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MENTAL HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/25/2019 07:41 AM/DISC: 02/25/2019 07:41 AM